EFICACIA Y SEGURIDAD A LARGO PLAZO DE

INEBILIZUMAB EN EL TRASTORNO DEL ESPECTRO

DE LA NEUROMIELITIS ÓPTICA: ANÁLISIS DE
PARTICIPANTES SEROPOSITIVOS A LA
ACUAPORINA-4-INMUNOGLOBULINA G QUE
TOMARON INEBILIZUMAB DURANTE ⩾4 AÑOS EN EL
ENSAYO N-MOMENTUM
BIOQUIMICA
DOCENTE : DR. ROSSE MARY YAÑEZ VILLANUEVA
ESTUDIANTES :
 Eficacia y seguridad a largo plazo de inebilizumab en el trastorno del espectro de la
neuromielitis óptica: análisis de participantes seropositivos para acuaporina-4-inmunoglobulina
G que tomaron inebilizumab durante ⩾4 años en el ensayo N-MOmentum

AUTORES : Mary Rensel, Aram Zabeti, Maureen A Mealy, Daniel

Cimbora, Dewei She, Jorn Drappa y Eliezer Katz

Revista de esclerosis múltiple – EE.UU.

Fecha de recepción: 14 de abril de 2021; revisado: 6 de agosto de 2021; aceptado: 22 agosto

2021
 TABLE OF CONTENTS

About me My experience
01 You can describe the topic of
the section here
03 You can describe the topic of
the section here

What I do My work
02 You can describe the topic of
the section here
04 You can describe the topic of
the section here
 ABOUT ME
Venus has a beautiful name and is the second planet from the
Sun. It’s terribly hot—even hotter than Mercury—and its
atmosphere is extremely poisonous. It’s the second-brightest
natural object in the night sky after the Moon
 EXPERIENCE

2014 - 2016 2016 - 2017

Venus is the second planet 1 2 Jupiter is the biggest
from the Sun planet of them all

2017 - 2019 2019 - 2021

Despite being red, Mars is 3 4 Saturn is a gas giant and
a cold place has several rings
 JOB POSITION 1

2015 - 2018

COMPANY NAME
Job - Position title here:
● Venus has a beautiful name
● Jupiter is the biggest planet of them all
● Mars is actually a very cold place
● Mercury is the closest planet to the Sun
 EDUCATION

2010 - 2015 2015 - 2017 2017 - 2021

Despite being red,

Venus is the second Mercury is the closest
Mars is a cold place
planet from the Sun planet to the Sun
full of iron
 Referencias bibliograficas
References
1. Bennett JL, O’Connor KC, Bar-Or A, et al. B
lymphocytes in neuromyelitis optica. Neurol
Neuroimmunol Neuroinflamm 2015; 2(3): e104.
2. Wingerchuk DM, Banwell B, Bennett JL, et al.
International consensus diagnostic criteria for
neuromyelitis optica spectrum disorders. Neurology
2015; 85: 177–189.
3. Viela Bio. Uplizna [package insert]. Gaithersburg,
MD: Viela Bio, 2020.
4. Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab
for the treatment of neuromyelitis optica spectrum
disorder (N-MOmentum): A double-blind,
randomised placebo-controlled phase 2/3 trial. Lancet
2019; 394: 1352–1363.
5. Chen D, Gallagher S, Monson NL, et al.
Inebilizumab, a B cell-depleting anti-CD19 antibody
for the treatment of autoimmune neurological
diseases: Insights from preclinical studies. J Clin Med
2016; 5: 107.
6. Cree BAC, Bennett JL, Sheehan M, et al. Placebocontrolled study in
neuromyelitis optica: Ethical
and design considerations. Mult Scler 2016; 22(7):
862–872.
7. Genentech Inc. Rituxan [package insert]. San
Francisco, CA: Genentech Inc, 2020
8. Genentech Inc. Ocrevus [package insert]. San
Francisco, CA: Genentech Inc, 2020.
9. Wingerchuk DM, Fujihara K, Palace J, et al. Longterm safety and
efficacy of eculizumab in aquaporin-4
IgG-positive NMOSD. Ann Neurol 2021; 89(6):
1088–1098.
10. Alexion Pharmaceuticals Inc. Soliris [package insert].
Cheshire, CT: Alexion Pharmaceuticals Inc, 2011.
11. Yamamura T, Kleiter I, Fujihara K, et al. Trial
of satralizumab in neuromyelitis optica spectrum
disorder. N Engl J Med 2019; 381: 2114–2124.
12. Lucas E, Weinshenker B, Blondeau K, et al. Infection
rates with satralizumab in patients with neuromyelitis
optica spectrum disorder (NMOSD): Results from the
phase 3 SAkura studies. In: MSVirtual 2020 (Virtual
meeting), 11–13 September 2020.
13. Forsthuber TG, Cimbora DM, Ratchford JN, et al.
B cell-based therapies in CNS autoimmunity:
Differentiating CD19 and CD20 as therapeutic
targets. Ther Adv Neurol Disord 2018; 11: 761697.
14. Focosi D, Tuccori M and Maggi F. Progressive
multifocal leukoencephalopathy and anti-CD20
monoclonal antibodies: What do we know after
20 years of rituximab. Rev Med Virol 2019; 29(6):
e2077